Showing 39 articles in COVID-19

  • Safety reporting continuity to protect patient safety and maintain compliance

    7 May 2020| Nola Cadman

    Scientists are working diligently to learn more about the Coronavirus and health boards are changing guidance to adapt to this newly available information. The response to this information varies on a regional and country level as does regulatory and submission guidance

  • Anti-viral surfaces could tackle COVID-19 crisis

    6 May 2020| PharmiWeb Editor

    Some of the world’s leading coatings specialists gathered virtually at the Royal Society of Chemistry to discuss how special surface technologies could be used to tackle the global COVID-19 pandemic.

  • Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark

    6 May 2020| PharmiWeb Editor

    Roche today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA)1 for its new Elecsys® Anti-SARS-CoV-2 antibody test. The test is designed to help determine if a patient has been exposed to the SARS-CoV-2 virus and if the patient has developed antibodies against SARS-CoV-2...

  • Pivotal to provide specialised clinical research services for new clinical trial with patients that have COVID-19

    5 May 2020| PharmiWeb Editor

    Pivotal, has announced today that it has been contracted to provide specialised clinical research services in a clinical trial to study the efficacy and safety of hyperimmune plasma...

  • Medidata Accelerates Launch of myMedidata Platform, Responding to COVID-19

    24 Apr 2020| PharmiWeb Editor

    Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes.

  • BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates

    22 Apr 2020| Pharmiweb editor

    MAINZ, Germany and NEW YORK, April 22, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE), have announced today that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 clinical trial for BioNTech’s BNT162 vaccine program to prevent COVID-19 infection.

  • Laboratory relocation firm offers free support for NHS

    22 Apr 2020| PharmiWeb Editor

    Specialist laboratory relocation and storage provider, Aport, is offering free support to the NHS in the regions surrounding its UK headquarters.

  • Sanofi and Luminostics to join forces on developing breakthrough COVID-19 smartphone-based self-testing solution

    16 Apr 2020| PharmiWeb Editor

    Sanofi and Luminostics have signed an agreement to evaluate a collaboration on a unique self-testing solution for COVID-19, using Luminostics’ innovative technology, and further adding to Sanofi’s ongoing efforts to fight the COVID-19 pandemic on multiple fronts.

  • NovaBiotics announces fast-track repurposing of its experimental drug Nylexa for COVID-19 trials and plans for earliest possible compassionate use

    14 Apr 2020| PharmiWeb Editor

    NovaBiotics, the clinical stage antimicrobials drug discovery company, announces the rapid repurposing of Nylexa for the ‘hidden killer’ underlying COVID-19: secondary bacterial lung infections.

  • Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

    14 Apr 2020| PharmiWeb Editor

    Sanofi and GSK today announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.

  • FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19

    9 Apr 2020| Pharmiweb editor

    Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, today announced that it has received clearance from the United States Food and Drug Administration (FDA)

  • Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of High-Dose Inhaled Nitric Oxide Therapy for COVID-19 Infection and Associated Lung Complications

    8 Apr 2020| Pharmiweb editor

    Study to investigate antiviral activity and improvement in oxygenation and pulmonary arterial pressure in patients suffering from COVID-19

  • Celltrion Healthcare secure 300 COVID-19 antibody candidates in efforts to develop antiviral

    8 Apr 2020| Pharmiweb editor

    Celltrion Group today announced its successful transition to the second phase of development for an antiviral treatment to fight the novel coronavirus (COVID-19) pandemic, following the completion of the first phase of securing 300 different types of antibodies that bind to the antigen last month. The library of antibodies was created using the blood of recovered patients in Korea.

  • The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response

    8 Apr 2020| PharmiWeb Editor

    Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation, a nonprofit charitable foundation, commits to make donations totaling $5 million in 2020 to support global COVID-19 relief efforts, including doubling its match for employees’ charitable donations to eligible organizations responding to the COVID-19 pandemic.

  • COVID-19: How lockdown could affect our long term health

    8 Apr 2020| PharmiWeb Editor

    Researchers at the University of East Anglia are launching a new project to track the health of the nation during lockdown, and they are looking for volunteers to take part.

  • CROMSOURCE Announces Launch of COVID-19 Clinical Trial

    7 Apr 2020| PharmiWeb Editor

    CROMSOURCE, an international contract research organization (CRO) with its global headquarters in Verona, Italy, has announced that it has initiated its first COVID-19 trial on behalf of a European pharmaceutical company.

  • PharmiWeb Advertising NHS COVID-19 Jobs for Free.

    7 Apr 2020| PharmiWeb Editor

    At this challenging time, we at PharmiWeb are pleased to step forward and do our small part by helping the NHS recruit urgently needed staff for the battle against COVID-19.

  • ZEGAMI BUILDS NEW TECH PLATFORM TO ANALYSE COVID-19 X-RAYS TO HELP SPEED UP DIAGNOSIS AND POTENTIALLY LEAD TO MORE EFFECTIVE TREATMENTS

    7 Apr 2020| PharmiWeb Editor

    Zegami, the Oxford University data visualisation spin-out, has developed a new machine learning model using x-rays of Covid-19 infected lungs, artificial intelligence techniques and data visualisation tools that could help medical professionals identify Coronavirus cases more effectively, but also potentially help provide a better idea of potential outcomes for patients, and even lead to more effective treatments.

  • GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

    7 Apr 2020| PharmiWeb Editor

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.

  • Independent Site Management Organisation Panthera prepares for COVID-19

    7 Apr 2020| PharmiWeb Editor

    The safety of clinical trial patients and staff is paramount. We are working with our clients in pharma and CROs to assess each trial to see if it needs to be suspended, delayed or if it can carry on in a way that is safe both for the clinicians and participants